Financial Burden of Cancer Drug Treatment in Lebanon |
Elias, Fadia
(Ministry of Public Health)
Khuri, Fadlo R (Emory University School of Medicine) Adib, Salim M (American University of Beirut, Faculty of Health Sciences) Karam, Rita (Lebanese University, Faculty of Medical Sciences) Harb, Hilda (Ministry of Public Health) Awar, May (American University of Beirut, Office of Grants & Contracts) Zalloua, Pierre (Lebanese American University, School of Medicine) Ammar, Walid (Ministry of Public Health) |
1 | International Medical Statistics (IMS) (2014). Available at: www.imshealth.com/en/about-us/news/ims-health-study:-cancerdrug-innovation-surges-as-cost-growth-moderates. |
2 | Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. (2013). Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol, 31, 3600-4. DOI |
3 | Lee CP, Chertow GM, Zenios SA (2009). An empiric estimate of the value of life: updating the renal dialysis costeffectiveness standard. Value Health, 12, 80-7. DOI |
4 | Luengo-Fernandez R, Leal J, Gray A, Sullivan R (2013). Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol, 14, 1165-74. DOI |
5 | Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011). Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst, 103, 117-28. DOI |
6 | Murray CJ, Kreuser J, Whang W (1994). Cost-effectiveness analysis and policy choices: investing in health systems. Bull World Health Organ, 72, 663-74. |
7 | National Cancer Registry (2008). MOPH. Available at: http://www.moph.gov.lb/Prevention/Surveillance/Pages/Cancer.aspx |
8 | National Cancer Treatment Guidelines (2012). MOPH. |
9 | National Health Accounts (2012). MOPH. |
10 | Newcomer LN, Gould B, Page RD, Donelan SA, Perkins M (2014). Changing physician incentives for affordable, quality cancer care: results of an episode payment model. J Oncol Pract, 10, 322-6. DOI |
11 | The Guardian (2012). Healthcare spending around the world, country by country. |
12 | World Bank (WB) (2015). Health expenditure, total (% of GDP) . |
13 | Yabroff KR, Lund J, Kepka D, Mariotto A (2011). Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev, 20, 2006-14. DOI |
14 | Zullig LL, Peppercorn JM, Schrag D, et al (2013). Financial distress, use of cost-coping strategies, and adherence to prescription medication among patients with cancer. J Oncol Pract, 9, 60-3. DOI |
15 | Ammar W (2003) Health system and reform in Lebanon. Lebanon: Ministry of Public Health. |
16 | Complete the reference of The Guardian to become: "The Guardian (2012). Healthcare spending around the world, country by country. www.theguardian.com/news/datablog/interactive/2012/jun/30/health-spending-map-world" |
17 | Elkin EB, Bach PB (2010). Cancer's next frontier: addressing high and increasing costs. JAMA, 303, 1086-7. DOI |
18 | American Cancer Society (2010).The global economic cost of cancer: Atlanta, Georgia, USA. |
19 | American Cancer Society (2008). Global cancer facts & figures. Atlanta, GA: USA. |
20 | Experts in Chronic Myeloid Leukemia (ECML) (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121, 4439-42. DOI |
21 | Himmelstein DU, Thorne D, Warren E, Woolhandler S (2009). Medical bankruptcy in the United States, 2007: results of a national study. Am J Med, 122, 741-6. DOI |
22 | Himmelstein DU, Woolhandler S (2012). Cost control in a parallel universe: medicare spending in the United States and Canada. Arch Intern Med, 172, 1764-6. DOI |
23 | World Health Report (2010). World Health Organization, Geneva, Swtizerland. |
24 | Yabroff KR, Lamont EB, Mariotto A, et al. (2008). Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst, 100, 630-41. DOI |
![]() |